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ABSTRACT 
 
OBJECTIVE: The objective of this selective evidence based medicine review is to determine 
whether or not a naltrexone implant is more effective than oral drug therapy and/or behavioral 
therapy at reducing heroin use in recovering heroin dependent adults. 
 
STUDY DESIGN: Review of three English language primary studies published from 2007 to 
2010. 
 
DATA SOURCE: Three randomized controlled trails comparing naltrexone implants to oral 
naltrexone, methadone, and usual aftercare found using Ovid, Pub med and Cochrane databases 
 
OUTCOME MEASURED: The primary outcomes measured by all three studies all three articles 
measured frequency of heroin use by self report 
 
RESULTS: Hulse et al. found that significantly more patients were abstaining from heroin at the 
6 month mark with implant naltrexone as compared to oral naltrexone. Kunøe et al. found that 
implant naltrexone was significantly better than usual aftercare at reducing total number of days 
of heroin use. Lobmair et al. found naltrexone implants to be similar to methadone treatment at 
reducing the number of days of heroin use per month. 
 
CONCLUSIONS: Hulse et al. found implantable naltrexone is more effective than oral, and
 
 
Kunøe et al. found it to be more effective than usual aftercare. Lobamier et al. concludes that 
methadone is equally effective to the naltrexone implant. These articles suggest that naltrexone 
implants are as or more effective than other therapies currently being offered. Future studies 
should be done in order identify individual patient factors that lead to higher efficacy and lower 
adverse events with implant therapy.  
 
KEY WORDS: Naltrexone implant, Relapse, opioids, and heroin
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INTRODUCTION 
 Heroin dependence can be more broadly defined as opioid dependence, and is described in 
the DSM IV.
 1
 It is a disease that is extremely prone to relapse, and is commonly treated with 
oral naltrexone. Naltrexone is an opioid receptor antagonist which functions in blocking the 
effects of opioids. Although it is very effective when taken as directed, success is limited by the 
heavy reliance placed on recovering individuals to consistently self-administer daily doses of 
naltrexone. An implantable version of the drug has recently been devised as way of side-stepping 
this obstacle. The implant ensures that patients will have therapeutic blood levels of naltrexone 
for up to 6 months at a time, theoretically increasing efficacy.
 1-3
 One study even reports that 
while oral naltrexone has only been as effective as placebo in reducing heroin cravings, the 
implantable version shows a significant reduction in cravings.
 4
 This paper evaluates three 
randomized controlled trials that compare the effectiveness of the naltrexone implant to more 
traditional oral and behavioral drug therapies in reducing heroin use in recovering opioid 
dependent adults.  
 As a health care provider, it is important to be able to identify heroin dependent patients and 
provide them with the best resources currently available. This is especially relevant in the 
northeastern United States where heroin abuse is disproportionately high when compared with 
the rest of the country.
5
 Data shows that individuals who begin abusing prescription opiates are 
at risk of later becoming heroin users in order to attain opiates more easily, at a lower cost, and 
achieve a greater “rush”. The rising prescription opiate abuse may be leading to higher rates of 
heroin abuse throughout the U.S. In fact, the number of users have risen substantially from 2002 
to 2010.
6
 Currently, these users are mainly concentrated in the Northeastern United states due to 
drug availability.
 5
 This trend can also be evidenced by the significant drop in age of first time 
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heroin use from an average of 25.5 years in 2009 to 21.3 years in 2010.
6
 Due to the fact that 
opioid dependence is a chronic condition, it is likely that younger first time heroin users will lead 
to an increased population of heroin dependent adults in the future. 
 Increased numbers of dependent individuals will increase the cost of healthcare in this area. 
In 2010 approximately 417,000 individuals sought treatment for heroin dependence.
 6
 The Office 
of National Drug Control Policy estimates that by 2020 there will be about 27 million patients in 
need of treatment for various substance use disorders, and they are expressing a great need for 
more healthcare professionals to be trained in substance abuse treatment.
7
  
Although current figures specific to the healthcare cost of heroin dependence are somewhat 
elusive, a 2001 study estimated the1996 U.S. health care cost of heroin addiction to be over 5 
billion dollars.
8
 With the number of users increasing combined with rising healthcare costs, 
today’s figures are likely to be substantially higher. Furthermore, the full economic burden of 
heroin addiction is great, easily more than four times the healthcare cost alone.
 8
   
 Heroin puts a user at risk of an array health problems that come not only from its nature as an 
opioid, but from other factors as well. Many of these health risks are infectious, and come about 
as a result of frequent intravenous administration of the drug with contaminated needles and non-
sterile injection sites. Hepatitis C, HIV, and bacterial infections of the injection site, blood, or 
heart valves are just a few examples. Some hazards come about as a result of the unregulated 
nature of  heroin. Varying potencies between batches make dosing inexact and contribute to 
overdose, possibly leading to respiratory depression, coma, and death. A variety of additives may 
be found in impure heroin, many of which can cause vascular damage. Other health problems 
arise over time, mainly as a result of the patient neglecting his or her own health while spending 
more time and energy in pursuit of the drug.
9 
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 Numerous relapses usually occur before a patient is finally able to end his or her heroin use. 
This fact is particularly troubling when considering that patients are more susceptible to heroin 
overdose during periods of relapse.
 2
 In an attempt to minimize instances of relapse, opioid 
dependence is usually treated with a combination of behavioral therapy and medication. 
Medication used in treatment typically includes methadone, buprenorphine, or naltrexone.
9
 
Treatment length varies widely according to medication and individual patient progress. Patients 
are generally encouraged to attend support groups such as Narcotics Anonymous indefinitely.  
 Naltrexone is generally very effective when taken as directed, but poor medication 
compliance leads to mixed clinical efficacy. Although medication compliance is an issue with 
almost any patient population, it is of special concern when dealing with recovering heroin 
dependent adults. In early recovery, this patient population generally lacks the financial, social, 
and mental stability needed to reliably self-administer medication, and unfortunately, the price of 
relapse is extremely high. An implantable form of naltrexone would theoretically eliminate this 
issue by removing the need for daily medication compliance.
 1, 2
  
OBJECTIVE 
The objective of this systematic review is to determine whether or not a naltrexone implant is 
more effective than oral drug therapy and/or behavioral therapy at reducing heroin use in 
recovering heroin dependent adults. 
METHODS 
 The three studies included in the systematic review were randomized controlled trials 
(RTCs). Hulse et al. was a randomized, double-blind, double-placebo controlled study.
 1
 Kunøe 
et al. used a randomized, open-label, trickle-inclusion study design.
 2
 Lobmaier et al. used a 
randomized, 2-arm, open-label study design.
 3
 The population that was studied included 
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recovering heroin dependent adults (18 years and older). The intervention being studied was a 
naltrexone implant designed release therapeutic naltrexone levels continuously for 5-6 months. 
These patients were compared against the control groups consisting of oral drug and/or behavior 
therapy. Oral drugs in the control groups included methadone in Lobmaier et al. and naltrexone 
in Hulse et al.
 1, 3
 The outcome measured was heroin use. Hulse et al. reported heroin use 
dichotomously as either use or abstinence, Kunøe et al. reported it as total number of days using 
heroin over the 180 day study period, and Lobmaier et al reported the average number of days 
used per month.
 1-3
  
 The Cochrane Database was searched first, followed by OVID and Pub med. Relevant 
articles published between December 2007 and September 2011were included. Key words 
searched were Naltrexone implant, Relapse, opioids, and heroin. All articles were published in 
english in peer reviewed journals. Articles were selected based on their relevance and the 
importance of their outcomes to patients (POEMS). Studies included were randomized controlled 
trials, they measured outcomes important to the patient (POEMS), and included patients that 
completed detox and were beginning recovery from heroin. Any studies involving subjects under 
18 years of age, or published in or before November 2007 were excluded. Statistics reported or 
used include p values, ANOVA F score, RRR, ARR, NNT. 
Table 1 - Demographics & Characteristics of included studies 
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Study Type # pts Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Hulse
1
 
2009 
RCT 70 18 yrs 
or older 
DSM-IV opioid (heroin) 
dependence,  willing to 
be randomized, residing 
in the Perth, Western 
Australia, metropolitan 
area; completion of 
preclinical screening 
and written consent 
3 + opioid overdoses in 
past month; treatment 
with oral naltrexone 
more than 4 times in 
the previous 3 months; 
previous sustained-
release naltrexone 
treatment;enrollment in 
other opioid research; 
pregnancy; active skin 
or other infections; 
contraindications to 
naltrexone 
9 Experimental 
group: single dose 
of 2.3 g of 
naltrexone implant 
(plus placebo 
tablets) 
 
Control group: oral 
naltrexone, 50 
mg/d, for 6 months 
(plus placebo 
implants)  
Kunøe
2
200
9 
RCT 56 18 yrs 
or older 
Opiate-dependent adults 
receiving abstinence-
oriented in-patient 
treatment 
Psychosis, pregnancy, 
and serious hepatic 
disease 
4 Experimental 
group: 20-pellet 
naltrexone implants 
(effective for 5-6 
months) 
 
Control group: 
Usual aftercare 
Lobmaier
3
2
010 
RCT 44 18 yrs 
or older 
Heroin-dependent 
inmate, pre-
incarceration heroin 
dependence, minimum 
of 2 months of sentence 
time remaining 
Untreated major 
depression or 
psychosis, severe 
hepatic impairment, 
pregnancy, currently in 
an agonist maintenance 
treatment program 
17 Experimental 
group: 20-pellet 
naltrexone implants 
(effective for 5-6 
months) 
 
Control group: 
Methadone 
treatment starting at 
30 mg per day and 
increasing to the 
recommended daily 
dose of 80-130 mg 
within 3 weeks 
 
OUTCOMES MEASURED 
All three articles measured frequency of heroin use by self report. 
RESULTS 
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 Efficacy of the naltrexone implant for reducing heroin use compared to oral therapy 
and/or behavioral therapy was reported as dichotomous data in Hulse et al. and continuous data 
in Kunøe et al. and Lobmaier et al. All three studies preformed intention to treat analysis. All 
three studies used the same intervention in their experimental groups (5-6 month naltrexone 
implant), and all three collected patient data over a 6 month period.
 1-3
 However, the intervention 
offered to each control group, as well as the way the data were reported varied between studies.  
 Hulse et al. offered oral naltrexone to the control group. They reported that only 7 out of 
the 34 patients were abstaining from heroin use in the oral naltrexone group at the end of six 
months, and 17 out of 35 were abstaining in the naltrexone implant group. This indicates that 
significantly more patients were abstaining from heroin at the 6 month mark with implant 
naltrexone as compared to oral naltrexone with a narrow 95% confidence interval (CI) of 0.90 - 
3.28 (Table 2). The relative risk reduction (RRR) and the absolute risk reduction (ARR) were 
large, 133% and  28% respectively. The number needed to treat (NNT) was calculated to be 4, 
implying that one more patient would be abstinent at the 6 month mark for every 4 patients 
treated with implant instead of oral naltrexone (Table 3).
 1 
 Kunøe et al. only specified that the control group would receive some form of “usual 
aftercare” as their treatment. Usual aftercare involved behavioral and/or oral drug therapy, but 
varied from patient to patient. They reported that the control group of “usual aftercare” patients 
had an average of 63.3 days of heroin use over the 180 day study period. Patients in the 
naltrexone implant group had an average of 17.9 days of heroin use over that same time period. 
This was found to be significant, indicating that implant naltrexone may be better than usual 
aftercare at reducing total number of days of heroin use. The values are reported as p<0.05 and a 
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95% CI of 14.1 - 77.3 (Table 2). They also reported an ANOVA F-score = 7.0 and a change in 
mean from baseline of 45.6 days, both of which are significant.
 2 
 Lobmair et al. offered methadone treatment to the control group. They found the mean 
number of days of heroin use per month to be 20.2 in the control group and 15.6 in the 
experimental group. This was not found to be significant (p>0.05). Large standard deviations 
(SD) in the number of days per month of heroin use in the control and experimental groups, 
12.56 and 14.97 respectively, were reported (Table 2). The author, however, reports significantly 
less heroin use in the experimental group if worst case analysis is not applied (p= 0.012).
 3
  
 Table 2 - Efficacy of naltrexone implant at preventing heroin use in recovering adults 
Study 
Incidence of heroin 
use in control group 
Incidence of heroin use in 
experimental group 
p-vale 
Odds Ratio 
(95% CI) 
Hulse
 1
 2009 
7/34 participants 
abstaining 
17/35 participants 
abstaining 
N/A (0.90 - 3.28) 
Kunøe
 2
 
2009 
63.6/180 days 17.9/180 days p< 0.05 (14.1-77.3) 
Lobmaier
 3
 
2010 
20.2 days per month 15.6 days per month p > 0.05 N/A 
 Table 3 - Treatment effects 
Study RRR ARR NNT 
Hulse
 1
 2009 133% 28% 4 
 
 Hulse et al. reported several study related adverse events. In this study, the experimental 
group and control group received implants that were completely identical with one exception: 
placebo pellets were used in the control group’s implants. Because of this, adverse events that 
related to the implantation site itself (wound swelling/erythema and wound hematoma) were 
calculated with the data gathered from all 69 participants. Furthermore, the data was calculated 
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with the assumption that use of oral naltrexone alone would not cause adverse events related to 
an implantation site. Under these assumptions, the number needed to harm (NNH) for the most 
serious adverse event, a wound hematoma, was 100. This suggests one wound hematoma will 
occur for every 100  patients receiving naltrexone implants. The NNH for implantation site 
erythema/edema was 34, making this less serious adverse event more likely. Other adverse 
events that were reported related to side effects of naltrexone itself. These adverse events 
include: erectile dysfunction, abdominal cramps, diarrhea, depression, metallic taste, and 
headache. With the exception of one patient who reported cramping and diarrhea at several of the 
follow-ups throughout the study, these medication side effects were only reported one time for 
each of the patients who experienced them. Considering the control and experimental groups had 
34 and 35 members, respectively, Table 4 may not be representative of a larger population. 
However, diarrhea was found in 4 members of the experimental group (one member with 
persistent diarrhea) and none from the control group. This may be because the experimental 
group had blood naltrexone levels at or above therapeutic level significantly more frequently 
than the control group, and diarrhea is one of the most common known side effects of naltrexone 
(Table 4).
 1
  
Table 4 - Adverse events with implant vs oral naltrexone 
Adverse Events Oral CER Implant EER RRI ARI NNH 
Wound Edema and Erythema  0%
a 
3%
b 
N/A 3% 34 
Wound Hematoma 0%
a 
1%
b 
N/A 1% 100 
Diarrhea 0% 9% N/A 9% 12 
Abdominal Cramps 0% 3% N/A 3% 34 
Erectile Dysfunction 0% 3% N/A 3% 34 
Headache 3% 3% 0% 0% N/A 
Depression 3% 0% -100% -3% -34 
Metallic Taste 3% 0% -100% -3% -34 
RRI= relative risk reduction; ARI= absolute risk reduction; NNH= number needed to harm; CER= control event 
rate; EER= experimental event rate 
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Negative NNH indicates benefit. 
a
Calculated assuming patients taking oral naltrexone without placebo implant would not develop implant-related 
adverse effects. 
b
Calculated assuming placebo and naltrexone implants would have similar implant-related adverse effects.  
 
 
  
 Lobmaier et al. reported compliance rates of study treatment in former inmates. In this 
study, the population focused on inmates with heroin dependence who were soon to be released 
from prison. In each case, detoxification began about a month before each inmate was released, 
and data was collected up to 6 months after release. Six months after beginning treatment, 69.6% 
of patients in the naltrexone implant group were continuing to receive the study-assigned 
treatment while only 23.8% of inmates in the methadone control group were receiving treatment. 
This indicates a significantly higher compliance rate (p=0.003) for inmates with naltrexone 
implants vs. oral methadone.
 3
   
DISCUSSION 
 
 Although the articles discussed in this paper focused on adults who were recovering from 
heroin dependence, naltrexone is effective in treating dependence of other opiates as well as 
alcohol. Consistent daily compliance with oral medication is an area of concern when treating 
any of these patients, and some studies are looking into the efficacy of the naltrexone implant in 
these populations.
 1
  
 Although the active component of the naltrexone implant has been FDA approved and 
widely used in the treatment of opioid dependence since 1984, the implantable version of the 
drug has not yet gained FDA approval in the United States.
1
 Despite this, some private U.S. 
clinics have been using the implant. These implants are in the form of naltrexone containing 
pellets formed with a biodegradable polymer. They are surgically implanted into a patient’s 
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abdominal wall. Sustained release naltrexone is currently approved in an injectable form under 
the trade name Vivitrol, however, this must be given on a monthly basis.
 1, 2, 10
  
 Naltrexone has been reported to cause nausea/vomiting/diarrhea, abdominal pain/cramping, 
constipation, depressed mood, difficulty falling/staying asleep, drowsiness, headache, 
anxiety/nervousness, irritability, rash, and muscle/joint pain. Among these, GI effects are the 
most common, and may occur in up to 10% of patients. More rare but serious side effects include 
confusion, severe vomiting/diarrhea, and hallucinations.
 10
      
 Naltrexone is contraindicated in patients with hepatic failure or acute hepatitis, patients 
taking opiate agonists, patients who have a current physical dependence to opioids, and patients 
with hypersensitivity to naltrexone or other ingredients in the given formulation. Patients should 
be opiate free for 7-10 days before beginning naltrexone therapy, as it can cause acute 
withdrawal. Naltrexone is relatively contraindicated in patients with active liver disease (LFTs 3 
times the upper limit of normal). Because naltrexone metabolites are eliminated in urine, it 
should be used with caution in patients with moderate to severe renal impairment.  The 
implantable version of naltrexone has some additional contraindications. These include infection 
of the implantation site and bleeding disorders.
 10
   
 The search for this systematic review was limited to articles published after November 
2007. The articles themselves also had some limitations. The lack of blinding in Kunøe et al. and 
Lobamier et al. was one of the most important.
 2, 3
 Also, the diversity of treatment regimens of 
the control group from Lobermier et al. limits the studies ability to make a straight forward 
comparison between treatment modalities.
 3
 Finally, the sample sizes in all three studies were 
small, limiting the generalizability of the findings. 
CONCLUSION 
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 The evidence  as to whether or not a naltrexone implant has better efficacy than oral 
therapy is conflicting. Hulse et al. supports the idea that implantable naltrexone is more effective 
than oral.
 1
 Kunøe et al. also found the implant to be more effective, however, the control group 
here lacked the uniformity needed for a clear comparison.
 2
 Lobamier et al. concludes that a 
different oral therapy, methadone, is equally effective to that of the naltrexone implant.
 3
 It is 
important to note, however, that methadone itself is an opiate. This type of treatment is 
principally very different from treatment with the opiate antagonist naltrexone. Given the above 
information, it seems that naltrexone implants would be a viable option for recovering heroin 
dependent adults. They would be especially useful in patients with opioid dependence who have 
found oral naltrexone to be effective at reducing cravings in the past, but failed therapy due to 
poor medication compliance.  
 It is seldom the case that a single therapy is the best choice across an entire patient 
population for a given disease. Correspondingly, it is unlikely that naltrexone implants are the 
best option for all recovering heroin/opiate dependent adults. However, the articles reviewed 
here suggest that these implants are as or more effective than other therapies currently being 
offered. Future studies should be done in order to identify patient factors that lead to higher 
efficacy and lower adverse events with implant therapy. This would allow clinicians to make 
better decisions as to which patients should be offered this more invasive but effective therapy 
instead of the traditional oral therapy.
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